<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HUMAN ALBUMIN GRIFOLS- albumin (human) solution </strong><br>GRIFOLS USA, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Human Albumin Grifols 20% safely and effectively.  See full prescribing information for Human Albumin Grifols 20%.<br>Human Albumin Grifols 20%<br>Albumin (Human) U.S.P.<br>20% solution <br>Initial U.S. Approval: 1995
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Indications and Usage</span>, <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian hyperstimulation syndrome</span> (<a href="#s7">1.5</a>), <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span> (<a href="#s9">1.7</a>), Prevention of Central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span> after Paracentesis Due to Cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span> (<a href="#s10">1.8</a>)       04/2012                                                                  
 </p>
<p class="Highlighta"><span class="Bold">Dosage and Administration</span>,  <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span>, Cardiopulmonary Bypass, Acute <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrosis</span>, <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span>, <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span>, Neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span>, Prevention of Central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span> after Paracentesis due to Cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span>   (<a href="#s12">2.1</a>)        04/2012
 </p>
<p class="Highlighta"><span class="Bold">Warnings and Precautions</span>,  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#s17">5.1</a>), <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span>/Hemodilution (<a href="#s18">5.2</a>), <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> (<a href="#s19">5.3</a>), <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Imbalance</span> (<a href="#s20">5.4</a>), Coagulation Abnormalities (<a href="#s21">5.5</a>), Laboratory Monitoring (<a href="#s22">5.6</a>), Application Precautions (<a href="#s23">5.7</a>)      04/2012
 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Human Albumin Grifols 20% is an albumin solution indicated for:
 </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span>. (<a href="#s3">1.1</a>)
</li>
<li>Cardiopulmonary bypass procedures. (<a href="#s4">1.2</a>)
</li>
<li>Acute <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>. (<a href="#s5">1.3</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span>. (<a href="#s6">1.4</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian hyperstimulation syndrome</span>. (<a href="#s7">1.5</a>)
</li>
<li>Neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>. (<a href="#s8">1.6</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult respiratory distress syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>). (<a href="#s9">1.7</a>)
</li>
<li>Prevention of central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> after paracentesis due to cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>. (<a href="#s10">1.8</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For Intravenous Use Only</span> </p>
<p class="Highlighta">Dosage and infusion rate should be adjusted to the patient's individual requirements.
 </p>
<table width="100%">
<col align="left" width="42.400%">
<col align="left" width="57.600%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Indication</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Dose</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: Initial dose of 20 g (including renal dialysis).<br>For <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>: initial dose of 12 to 25 g (<a href="#s12">2.1</a>)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Cardiopulmonary bypass procedures
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: Initial dose of 25 g (<a href="#s12">2.1</a>)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Acute <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 25 g together with diuretic once a day for 7 - 10 days (<a href="#s12">2.1</a>)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 50 to 75 g<br>For pre- and post-operative <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>: 50 to 75 g.<br>For burn therapy after the first 24 h: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL.<br>Third space protein loss due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: initial dose of 50 to 100 g  (<a href="#s12">2.1</a>)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian hyperstimulation syndrome</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 50 g to 100 g over 4 hours and repeated at 4 - 12 hour intervals as necessary (<a href="#s12">2.1</a>)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">1 g per kilogram body weight prior to or during exchange transfusion (<a href="#s12">2.1</a>)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult respiratory distress syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>)
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary (<a href="#s12">2.1</a>)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Prevention of central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> after paracentesis due to cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 8 g for every 1000 mL of ascitic fluid removed  (<a href="#s12">2.1</a>)
</td>
</tr>
</tbody>
</table>
<p class="Highlighta">Do not dilute with sterile water for injection as this may cause <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> in recipients. (<a href="#s23">5.7</a>)
 </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Human Albumin Grifols 20% is a solution containing 200 g per L of total protein of which at least 95% is human albumin.
  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to albumin preparations or to any of the excipients.
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> with normal or increased intravascular volume. (<a href="#s15">4</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Suspicion of allergic or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> requires immediate discontinuation of the injection and implementation of appropriate medical treatment. (<a href="#s17">5.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span> may occur if the dosage and rate of infusion are not adjusted to the patient's volume status. Use with caution in conditions where <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> and its consequences or hemodilution could represent a special risk to the patient. (<a href="#s18">5.2</a>)
</li>
<li>When concentrated albumin is administered, care must be taken to assure adequate hydration of the patient. (<a href="#s19">5.3</a>)
</li>
<li>Monitor electrolytes, coagulation and hematology parameters, and hemodynamic status when albumin is administered. (<a href="#s20">5.4</a>, <a href="#s21">5.5</a>, <a href="#s22">5.6</a>)
</li>
<li>Do not dilute with sterile water for injection.  (<a href="#s23">5.7</a>)
</li>
<li>This product is made from human plasma and may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease agent. (<a href="#s24">5.8</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions are anaphylactoid type reactions. (<a href="#s25">6</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals Inc. at 1-888-GRIFOLS (1-888-474-3657) or FDA at 1-800-FDA-1088 or
</span><span class="Bold Underline">www.fda.gov/medwatch</span>.
 </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Pregnancy: No human or animal data.  Use only if clearly needed. (<a href="#s30">8.1</a>)
</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span>
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Cardiopulmonary Bypass Procedures (Treatment Adjunct)
</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Acute <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrosis</span> (Treatment Adjunct)
</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span>
</a></h2>
<h2><a href="#section-1.5" class="toc">1.5 <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span>
</a></h2>
<h2><a href="#section-1.6" class="toc">1.6 Neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span>
</a></h2>
<h2><a href="#section-1.7" class="toc">1.7 <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>) (Treatment Adjunct)
</a></h2>
<h2><a href="#section-1.8" class="toc">1.8 Prevention of Central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span> after Paracentesis due to Cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span> (Treatment Adjunct)
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Administration
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span>/Hemodilution
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Imbalance</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Coagulation Abnormalities
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Laboratory Monitoring
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Application Precautions
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Transmissible Infectious Agents
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery
</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-10.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-11" class="toc">15 REFERENCES
</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span>
</h2>
<p class="First">For restoration and maintenance of circulating blood volume where <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> is demonstrated and colloid use is appropriate. When <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> is long standing and <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> exists accompanied by adequate hydration or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, 20-25% albumin solutions should be used.<span class="Sup">1,2,3</span></p>
<p><span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">Acute liver failure</span> is a special situation in which both <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> and <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> can be present. Human Albumin Grifols<span class="Sup">®</span> 20% can be used in such cases.<span class="Sup">1</span></p>
<p>Human Albumin Grifols 20% may be of value in the treatment of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in renal dialysis patients.<span class="Sup">1</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Cardiopulmonary Bypass Procedures (Treatment Adjunct)
</h2>
<p class="First">Preoperative dilution of blood using albumin and crystalloid can be used in cardiopulmonary bypass procedures. Albumin also may be used in the priming fluid.<span class="Sup">4,5,6</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Acute <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrosis</span> (Treatment Adjunct)
</h2>
<p class="First">Human Albumin Grifols 20% may be used to treat <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> in patients with acute <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> who are refractory to cyclophosphamide, corticosteroid therapy or diuretics.<span class="Sup">1,2,7</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-1.4"></a><p></p>
<h2>1.4 <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span>
</h2>
<p class="First">Human Albumin Grifols 20% may be indicated for subjects with <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> who are critically ill and/or  actively <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. When albumin deficit is the result of excessive protein loss, the effect of Human Albumin Grifols 20% administration will be temporary unless the underlying disorder is reversed.<span class="Sup">8,9,10</span></p>
<p>Septic patients and patients undergoing major surgery may lose more than half of their circulating plasma volume.<span class="Sup">1,11</span>  Treatment with Human Albumin Grifols 20% may be of value in such cases, especially when plasma colloid oncotic pressure is abnormally low.<span class="Sup">1</span>  In the first 24 hours after thermal injury, large volumes of crystalloids are infused to restore the depleted extracellular fluid volume. Beyond 24 hours, Human Albumin Grifols 20% can be used to maintain plasma colloid osmotic pressure.<span class="Sup">2,12,13</span></p>
<p>Protein loss from the third space due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (acute <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="439045" conceptname="Mediastinitis">mediastinitis</span> or extensive <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>) may require treatment with an infusion of albumin.<span class="Sup">14,15</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-1.5"></a><p></p>
<h2>1.5 <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span>
</h2>
<p class="First">Human Albumin Grifols 20% may be used as a plasma volume expander in fluid management relating to severe forms of <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">ovarian hyperstimulation syndrome</span>.<span class="Sup">16,17</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-1.6"></a><p></p>
<h2>1.6 Neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span>
</h2>
<p class="First">Human Albumin Grifols 20% is indicated for the treatment of neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>. It may be used prior to or during an exchange procedure in an attempt to bind free bilirubin and  enhance its excretion.<span class="Sup">18,19,20</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-1.7"></a><p></p>
<h2>1.7 <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>) (Treatment Adjunct)
</h2>
<p class="First">Human Albumin Grifols 20% infusions may be indicated in conjunction with diuretics to correct <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> and <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> associated with <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>.<span class="Sup">6,21</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-1.8"></a><p></p>
<h2>1.8 Prevention of Central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span> after Paracentesis due to Cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span> (Treatment Adjunct)
</h2>
<p class="First">Human Albumin Grifols 20% may be used to maintain cardiovascular function following removal of large volumes of ascitic fluid after paracentesis due to cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>.<span class="Sup">2,22,23,24</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s11"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First"><span class="Bold">For Intravenous Use Only</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage
</h2>
<p class="First">Adjust the concentration, dosage and infusion rate of the albumin preparation to the patient's individual requirements.
</p>
<p>The dose required depends on the patient's body weight, severity of injury/illness and on continuing fluid and protein losses. Use adequacy of circulating blood volume, not plasma albumin levels, to determine the dose required.
</p>
<table width="100%">
<col align="left" width="38.950%">
<col align="left" width="61.050%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Indication</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Dose</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: Initial dose of 20 g.<br>If hemodynamic stability is not achieved within 15 to 30 minutes, an additional dose may be given.<br>Hemodilution may follow administration of Human Albumin Grifols 20%. <br><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> resulting from <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> should be corrected by administration of compatible red blood cells or compatible whole blood.<br>For <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>: initial dose of 12 to 25 g. An infusion rate of 1-2 mL per min is usually indicated.<br>For renal dialysis, the initial dose should not exceed 20 g and patients should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Cardiopulmonary bypass procedures
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: Initial dose of 25 g. Additional amounts may be administered as clinically indicated.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Acute <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 25 g together with diuretic once a day for 7 - 10 days.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 50  to 75 g.<br>For pre- and post-operative <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>: 50 to 75 g.<br>In <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, therapy usually starts with administration of large volumes of crystalloid solution to maintain plasma volume. After 24 hours: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL or a serum protein concentration of 5.2 g per 100 mL.<br>Third space protein loss due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: initial dose of 50 to 100 g. An infusion rate of 1-2 mL per minute is usually indicated in the absence of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.  Treatment should always be guided by hemodynamic response.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian hyperstimulation syndrome</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 50 g to 100 g over 4 hours and repeated at 4-12 hour intervals as necessary, when infusion of normal saline fails to achieve or maintain hemodynamic stability and urine output.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">1 g per kilogram body weight prior to or during exchange transfusion.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult respiratory distress syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>)
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary.
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Prevention of central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> after paracentesis due to cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">Adults: 8 g for every 1000 mL of ascitic fluid removed.
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Administration
</h2>
<p class="First">Intravenous use only
</p>
<ul class="Disc">
<li>Human Albumin Grifols 20% is a clear and slightly viscous solution. Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the solution is turbid or if there is sediment in the bottle.
</li>
<li>Do not freeze.
</li>
<li>Warm product to room temperature before use if large volumes are administered.
</li>
<li>Human Albumin Grifols 20% contains no preservatives. Do not begin administration more than 4 hours after the container has been entered. Discard unused portion.
</li>
<li>Do not dilute with sterile water for injection. The product can be diluted in an isotonic solution (e.g., 5% Dextrose in Water or 0.9% sodium chloride) [see <span class="Italics">Warnings and Precautions</span> (<a href="#s23">5.7</a>)].
</li>
<li>Adjust the infusion rate to the individual circumstances and the indication.
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s14"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Human Albumin Grifols 20% is a solution containing 200 g per L of total protein of which at least 95% is human albumin.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s15"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to albumin preparations or to any of the excipients.
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> with normal or increased intravascular volume.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s16"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<ul class="Disc"><li>Suspicion of allergic or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> requires immediate discontinuation of the infusion and implementation of appropriate medical treatment.
</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span>/Hemodilution
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span> may occur if the dosage and rate of infusion are not adjusted to the patient's volume status . At the first clinical signs of cardiovascular overload (<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, jugular venous <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>), the infusion must be slowed or stopped immediately.
</p>
<p>Use albumin with caution in conditions where <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> and its consequences or hemodilution could represent a special risk to the patient. Examples of such conditions are:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Decompensated heart failure</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">Esophageal varices</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Hemorrhagic diathesis</span>
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>
</li>
<li>Renal and post-renal <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>
</h2>
<p class="First">The colloid-osmotic effect of human albumin 20% is approximately four times that of blood plasma. Therefore, when concentrated albumin is administered, care must be taken to assure adequate hydration of the patient. Patients should be monitored carefully to guard against circulatory overload and hyperhydration. Patients with marked <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> require administration of additional fluids.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Imbalance</span>
</h2>
<p class="First">20% - 25% human albumin solutions are relatively low in electrolytes compared to 4% - 5% human albumin solutions. Monitor regularly  the electrolyte status of the patient and take appropriate steps to restore or maintain the electrolyte balance when albumin is administered.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Coagulation Abnormalities
</h2>
<p class="First">Regular monitoring of coagulation and hematology parameters is  necessary if comparatively large volumes are to be replaced. Care must be taken to ensure adequate substitution of other blood constituents (coagulation factors, electrolytes, platelets and erythrocytes).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Laboratory Monitoring
</h2>
<p class="First">Monitor regularly hemodynamic parameters during administration of Human Albumin Grifols 20%; this may include:
</p>
<ul class="Disc">
<li>Arterial blood pressure and pulse rate
</li>
<li>Central venous pressure
</li>
<li>Pulmonary artery occlusion pressure
</li>
<li>Urine output
</li>
<li>Electrolytes
</li>
<li>Hematocrit/hemoglobin
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Application Precautions
</h2>
<p class="First">Human Albumin Grifols 20% must not be diluted with sterile water for injection as this may cause <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> in recipients. The product can be diluted in an isotonic solution (e.g., 5% Dextrose in Water or 0.9% sodium chloride) [see <span class="Italics">Dosage and Administration</span> (<a href="#s13">2.2</a>)].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Transmissible Infectious Agents
</h2>
<p class="First">Albumin is a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for Human Albumin Grifols 20%.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s25"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The most serious adverse reactions are <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>. The most common adverse reactions are anaphylactoid type reactions.
</p>
<p>Adverse reactions to Human Albumin Grifols 20% normally resolve when the infusion rate is slowed or the infusion is stopped. In case of severe reactions, the infusion is stopped and appropriate treatment initiated.
</p>
<div class="Section" data-sectionCode="34092-7">
<a name="s26"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">No clinical studies were done using Human Albumin Grifols 20%.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience
</h2>
<p class="First"><span class="Italics">Because adverse reactions are reported voluntarily post-approval from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to product exposure. The following adverse reactions have been identified during post-approval use of human albumin, including Human Albumin Grifols (all strengths) in decreasing order of significance:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s28"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First">Human Albumin Grifols 20% must not be mixed with other medicinal products.
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s29"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s30"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with Human Albumin Grifols 20%. It is also not known whether Human Albumin Grifols 20% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Human Albumin Grifols 20% should be given to a pregnant woman only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s31"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery
</h2>
<p class="First">No human or animal data.  Use only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s32"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">No human or animal data.  Use only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s33"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">No human or animal data. Use only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s34"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">No human or animal data. Use only if clearly needed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s35"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">Human Albumin Grifols 20% is a sterile aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). Human Albumin Grifols 20% is prepared by a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> alcohol fractionation method from pooled human plasma obtained from venous blood. The product is stabilized with 0.08 millimole sodium caprylate and 0.08 millimole sodium acetyltryptophanate per gram of protein. The colloid osmotic effect of human albumin 20% is approximately four times that of normal human plasma.
</p>
<p>A liter of Human Albumin Grifols 20% solution contains 130 - 160 milliequivalents of sodium ion. The aluminium content of the solution is not more than 200 micrograms per liter during the shelf life of the product. The product contains no preservatives.
</p>
<p>Human Albumin Grifols 20% is manufactured from Source Plasma collected from FDA approved plasmapheresis centers in the United States. Human Albumin Grifols 20% is heated at 60 °C for ten hours against the possibility of transmitting viruses.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s36"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s37"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Human Albumin accounts for more than half of the total protein in the plasma and represents about 10% of protein synthesis activity by the liver. Human Albumin 20% has a corresponding hyperoncotic effect.
</p>
<p>The primary physiological function of albumin results from its contribution to plasma colloid oncotic pressure and transport function. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Other physiological functions include antioxidant properties; free radical scavenging and capillary membrane integrity.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s38"></a><a name="section-10.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">Albumin is distributed throughout the extracellular space and more than 60% of the body albumin pool is located in the extravascular fluid compartment. Albumin has a circulating life span of 15 - 20 days, with a turnover of approximately 15 g per day. The balance between synthesis and breakdown is normally achieved by feedback regulation. Elimination is predominantly intracellular and due to lysosome proteases.
</p>
<p>In healthy subjects, less than 10% of infused albumin leaves the intravascular compartment during the first 2 hours following infusion. There is considerable individual variation in the effect of albumin on plasma volume. In some patients the plasma volume can remain elevated for several hours. In critically ill patients, however, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s39"></a><a name="section-11"></a><p></p>
<h1>15 REFERENCES
</h1>
<ol class="Arabic">
<li>Tullis, J.L., "Albumin: 1. Background and Use, 2. Guidelines for Clinical Use". JAMA 237; 355-360, 460-463, 1977.
</li>
<li>Vermeulen LC et al.: A Paradigm for Consensus. Arch. Intern. Med. 1995; 155:373-379.
</li>
<li>SAFE Study investigators: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350:2247-2256.
</li>
<li>Sedrakyan A, Gondek K, Paltiel D, et al. Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest 2003;123:1853-1857.
</li>
<li>Russell JA, Navickis RJ, Wilkes MM. Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. J Cardiothorac Vasc Anesth 2004;18:429-37.
</li>
<li>American Thoracic Society. Evidence-based colloid use in the critically ill: American Thoracic Society consensus statement. Am J Respir Crit Care Med. 2004; 170:1247-59.
</li>
<li>Fliser D, Zurbrüggen I, Mutschler E, et al. Coadministration of albumin and furosemide in patients with <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>. Kidney Int 1999; 55:629-34.
</li>
<li>Mendez CM, McClain CJ, Marsano LS: Albumin Therapy in Clinical Practice. Nutrition in Clinical Practice 2005;20:314-320.
</li>
<li>Haynes GR, Navickis RJ, Wilkes MM. Albumin administration-what is the evidence of clinical benefit? A systematic review of randomized controlled trials. Eur J Anaesthesiol. 2003 Oct;20(10):771-93.
</li>
<li>Vincent JL, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med. 2004;32:2029-38.
</li>
<li>Skillman JJ, Tanenbaum BJ. Current Topics in Surgical Research. Vol. 2. New York: Academic Press; 1970:523.
</li>
<li>Muir IA, Barclay TL. <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span> and their treatment. Chicago: Year Book Medical Publishers; 1974.
</li>
<li>Pruitt BA Jr, Goodwin CW Jr. Current treatment of the extensively burned patient. Surg Annu. 1983;15:331-64.
</li>
<li>Clowes GHA Jr, Vucinic M, Weidner MG: Circulatory and metabolic alterations associated with survival or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>: clinical analysis of 25 cases. Ann Surg 1966; 166:866-85.
</li>
<li>Sort P, Navasa M, Arroyo V, et al: Effect of intravenous albumin on <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and mortality in patients with cirrhosis and spontaneous bacterial <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>. N Engl J Med 1999, 341:403-409.
</li>
<li>Aboulghar M, Evers JH, Al Inany H: Intravenous albumin for preventing severe <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">ovarian hyperstimulation syndrome</span>: a Cochrane review. Hum.Reprod. 2002;17:3027-3032.
</li>
<li>Practice Committee of the American Society for Reproductive Medicine. <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian hyperstimulation syndrome</span>. Fertil.Steril. 2006;86:S178-S183.
</li>
<li>Tsao YC, Yu VY: Albumin in management of neonatal hyperbilirubinaemia. Arch Dis Child 1972;47:250-256.
</li>
<li>Practice parameter: management of <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> in the healthy term newborn. Pediatrics 1994;94(4 pt 1):558-62.
</li>
<li>Dennery PA, Seidman DS, Stevenson DK. Neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>. N Eng J Med 2001;344 :581-90.
</li>
<li>Martin GS et al.: A randomized, controlled trail of furosemide with or without albumin in hypoproteinemic patients with acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">lung injury</span>. Crit. Care Med. 2005; 33: 1681-1687.
</li>
<li>Ginés P, Cárdenas A, Arroyo V, et al. Management of cirrhosis and <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>. N Engl J Med. 2004;350:1646-54.
</li>
<li>Runyon BA. AASLD Practice Guidelines. Management of adult patients with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> due to cirrhosis. Hepatology 2009; 49(6):2087-107.
</li>
<li>Moore KP, Wong F, Ginés P, et al. The management of <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> in cirrhosis: report on the consensus conference of the International <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span> Club. Hepatology 2003; 38:258-66.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s40"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Human Albumin Grifols 20% is supplied in single-use, individually laser etched vials.
</p>
<p>The following vial sizes of Human Albumin Grifols 20% are available:
</p>
<p><span class="Underline">NDC Number    Fill Size    Grams Protein</span><br>61953-0001-1    50 mL       10 g<br>61953-0001-2    100 mL     20 g
</p>
<p>Each vial has an integral suspension band and a label with a peel-off strip showing the product name and lot number.
</p>
<p>Human Albumin Grifols 20% is stable for three years provided the storage temperature does not exceed 30 °C. Protect from freezing.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s41"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">This product is usually given in a hospital setting.
</p>
<p>Inform patients being treated with Human Albumin Grifols 20% about the risks and benefits of  its use [see <span class="Italics">Adverse Reactions</span> (<a href="#s25">6</a>)].
</p>
<p>Inform patients to immediately report the following signs and symptoms to their physician:
</p>
<ul class="Disc">
<li>Allergic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactic type reactions</span> [see <span class="Italics">Warnings and Precautions</span> (<a href="#s17">5.1</a>)].
</li>
<li>Cardiovascular overload (e.g., <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and jugular venous <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>) [see <span class="Italics">Warnings and Precautions</span> (<a href="#s18">5.2</a>)].
</li>
<li><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">Increased blood pressure</span>, raised venous pressure and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> [see <span class="Italics">Warnings and Precautions</span> (<a href="#s18">5.2</a>)].
</li>
</ul>
<p>Inform patients that Human Albumin Grifols 20% is a derivative of human plasma and may contain infectious agents that cause disease (e.g., viruses, and theoretically, the CJD agent). Inform patients that the risk that Human Albumin Grifols 20% may transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing the donated plasma for certain viral agents and by the inactivation and/or removal of certain viruses during the manufacturing process [see <span class="Italics">Warnings and Precautions</span> (<a href="#s24">5.8</a>)].
</p>
<p>Manufactured by: <br><span class="Bold">Instituto Grifols, S.A.<br></span>Barcelona, Spain<br>U.S. License No. 1181
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s42"></a><a name="section-14"></a><p></p>
<p class="First">Principal Display Panel – 50 mL Vial
</p>
<p>NDC 61953-0001-3
</p>
<p>Albumin (Human) U.S.P. Human Albumin Grifols® 20%
</p>
<p>10.0 g 50 mL     Rx only.<br>Dosage and directions for administration, see package insert.<br>Store at temperatures not exceeding 30 °C<br>DO NOT USE IF TURBID. DO NOT BEGIN ADMINISTRATION MORE THAN<br>4 HOURS AFTER THE CONTAINER HAS BEEN ENTERED.
</p>
<p>Manufactured by <span class="Bold">Instituto Grifols, S.A.</span> Barcelona – SPAIN U.S. License No. 1181<br><a name="f01"></a><img alt="Principal Display Panel – 50 mL Vial
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a43c5ed6-7423-4ee5-8acb-5fccc2d7b6cc&amp;name=huma1-0006-01.jpg"><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s43"></a><a name="section-15"></a><p></p>
<p class="First">Principal Display Panel – 50 mL Carton
</p>
<p><span class="Bold">GRIFOLS</span></p>
<p>NDC 61953-0001-1
</p>
<p>Albumin (Human)<br>U.S.P.<br>Human Albumin<br>Grifols®
</p>
<p>20%     Solution<br>10.0 g     50 mL
</p>
<p>DO NOT USE IF TURBID.<br>DO NOT BEGIN ADMINISTRATION<br>MORE THAN 4 HOURS AFTER<br>THE CONTAINER HAS<br>BEEN ENTERED.
</p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel – 50 mL Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a43c5ed6-7423-4ee5-8acb-5fccc2d7b6cc&amp;name=huma1-0006-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s44"></a><a name="section-16"></a><p></p>
<p class="First">Principal Display Panel – 100 mL Vial
</p>
<p><span class="Bold">GRIFOLS</span></p>
<p>NDC 61953-0001-4
</p>
<p>Albumin (Human) U.S.P. Human Albumin Grifols® 20% 100 mL
</p>
<p>20 g 100 mL     Rx only.<br>CONTENTS: Each 100 mL contains 20 grams Albumin (Human) in aqueous diluent.<br>Osmotically equivalent to 400 mL of plasma. Sodium range 130-160 milliequivalents per liter.<br>Dosage and directions for administration, see package insert.<br>Contains no preservatives. Store at temperatures not exceeding 30 °C<br>DO NOT USE IF TURBID.<br>DO NOT BEGIN ADMINISTRATION MORE THAN 4 HOURS AFTER THE CONTAINER HAS BEEN ENTERED.
</p>
<p>Manufactured by <span class="Bold">Instituto Grifols, S.A.</span> Barcelona – SPAIN, U.S. License No. 1181<br><a name="f03"></a><img alt="Principal Display Panel – 100 mL Vial
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a43c5ed6-7423-4ee5-8acb-5fccc2d7b6cc&amp;name=huma1-0006-03.jpg"><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s45"></a><a name="section-17"></a><p></p>
<p class="First">Principal Display Panel – 100 mL Carton
</p>
<p><span class="Bold">GRIFOLS</span></p>
<p>NDC 61953-0001-2
</p>
<p>Albumin (Human)<br>U.S.P.<br>Human Albumin<br>Grifols®
</p>
<p>20%     Solution<br>20 g     100 mL
</p>
<p>DO NOT USE IF TURBID.<br>DO NOT BEGIN<br>ADMINISTRATION MORE<br>THAN 4 HOURS AFTER<br>THE CONTAINER HAS<br>BEEN ENTERED.
</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel – 100 mL Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a43c5ed6-7423-4ee5-8acb-5fccc2d7b6cc&amp;name=huma1-0006-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HUMAN ALBUMIN GRIFOLS 		
					</strong><br><span class="contentTableReg">albumin (human) solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61953-0001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Albumin (Human)</strong> (Albumin (Human)) </td>
<td class="formItem">Albumin (Human)</td>
<td class="formItem">10 g  in 50 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Caprylate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Acetyltryptophanate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61953-0001-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61953-0001-3</td>
<td class="formItem">50 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:61953-0001-2</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:61953-0001-4</td>
<td class="formItem">100 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103352</td>
<td class="formItem">02/17/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>GRIFOLS USA, LLC
							(048987452)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Instituto Grifols, S.A. </td>
<td class="formItem"></td>
<td class="formItem">465562213</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fa53d149-fe43-49b1-b683-6de921628fc2</div>
<div>Set id: a43c5ed6-7423-4ee5-8acb-5fccc2d7b6cc</div>
<div>Version: 6</div>
<div>Effective Time: 20131219</div>
</div>
</div> <div class="DistributorName">GRIFOLS USA, LLC</div></p>
</body></html>
